I am excited to join with Dr. Michael L. Lomax, President & CEO, UNCF; Dr. James Gillespie, President & Co-Founder, Center for Healthcare Innovation (CHI); and Dr. Chad Womack, Co-Founder and Executive Director of the Ernest E. Just Life Science Society on a collaboration to create new pathways to careers in the biopharmaceutical industry.
Building a more just and equitable health care system must focus on increasing diverse talent in our industry. We are committed to hiring and retaining diverse talent and promoting a culture of inclusion within our companies so that the biopharmaceutical industry’s workforce reflects the rich diversity of the United States.
To that end, this October we’re partnering with UNCF, CHI and the Ernest E. Just Life Science Society to host a two-day, free virtual summit for graduate students, post-doctoral trainees, faculty, PhRMA member companies and other community partners to learn about career pathways and increasing diverse talent within the industry. I know Dr. Lomax, Dr. Gillespie and Dr. Womack are as excited as I am to work together on this first-of-its-kind of event:
- “The UNCF is pleased to support PhRMA’s inaugural Pathways to Success in Biopharma Summit. We are pleased to participate in groundbreaking discussions about how historically black colleges and universities can contribute their extraordinary talent to the biopharmaceutical industry, and develop the next-generation of corporate leadership for the industry,” said Dr. Michael L. Lomax, President and CEO of the UNCF.
- “The summit will be a great opportunity for diverse graduate students to learn more about the global biopharmaceutical industry,” said Dr. James Gillespie, President and Co-Founder of the Center for Healthcare Innovation. “It is imperative that researchers, scientists, executives and other professionals of tomorrow are well-positioned to serve the increasingly diverse patient population across the United States."
- “We are excited to collaborate with PhRMA on this summit,” said Dr. Chad Womack, Co-Founder of the Ernest E. Just Life Science Society. “The summit represents a wonderful opportunity for diverse students at various stages of professional development to explore a variety of career pathways in the life science industry.”
The summit is a unique opportunity for students and faculty from diverse backgrounds to engage with biopharma recruiters and employees at different stages of their careers, discover potential internships and career opportunities, and learn about other pathways to the industry. We’ll offer panels, breakouts and a company exhibition hall spotlighting potential career opportunities in an exciting industry dedicated to pursuing new science and discovering innovative medicines.
Details on the summit can be found below. Space is limited, so please register soon here.
Who:
- HBCU and MSI graduate students and post-doctoral trainees, together with company recruiters and industry leaders
When:
- Oct 27: Virtual panels from 12:30 - 4:45 p.m. ET
- Oct 28: Opportunities to connect in the virtual exhibition hall from 12:00 PM - 3:00 p.m. ET
This summit is hosted as part of PhRMA’s Equity Initiative and driven by industry-wide efforts to build a workforce that better reflects the diversity of the United States. Learn more at phrma.org/equity
Stephen J. Ubl
Stephen J. Ubl is president and chief executive officer of the Pharmaceutical Research and Manufacturers of America (PhRMA), which represents America’s leading biopharmaceutical research companies. The U.S. biopharmaceutical sector directly employs more than 800,000 Americans and invests more than $100 billion in research and development annually – more than any other industry in America.
Ubl leads PhRMA’s work preserving and strengthening a health care and economic environment that encourages medical innovation, new drug discovery and access to life-saving medicines. Ubl is recognized around the world as a leading health care advocate and policy expert who collaborates successfully with diverse stakeholder groups – including patient and physician groups, regulators, public and private payers, and global trade organizations – to help ensure timely patient access to innovative treatments and cures. The New York Times writes, “If anyone can find areas of agreement with the critics, or at least work productively with them, it may be Mr. Ubl. He is more conversant with the intricacies of health policy, and more adept at the politics."
Previously, Ubl served as president and CEO of medical technology association AdvaMed, where he helped facilitate landmark reforms related to the U.S. Food and Drug Administration product review process and Medicare’s coverage and reimbursement of medical technologies. He led the industry’s defense of breakthrough R&D, successfully delaying an innovation-stifling device tax, and, in 2013, was recognized by a leading industry publication as one of 10 people to have a lasting impact on the medical technology industry.
Ubl has worked extensively with patient advocacy organizations in health policy, including longstanding service on the board of the National Health Council, a leading umbrella organization for voluntary health care organizations and has been personally involved with JDRF (formerly known as the Juvenile Diabetes Research Foundation).
He is routinely recognized as one of Washington’s most effective advocates. Ubl has been recognized on Business Insider’s “DC Healthcare Power Players” and Modern Healthcare’s “100 Most Influential People in Healthcare.” He is identified as a top health influencer by Medical Marketing & Media and PR Week magazines.
https://www.linkedin.com/in/steveubl/
President and Chief Executive Officer
Staffing up: Building the future biopharma workforce to keep America in the lead
Nearly 80 researchers advocate on Capitol Hill
Congratulations to our 2026 Working for Cures Employee Champions
Manufacturing U.S. jobs and breakthroughs
Historic biopharmaceutical investments: A prescription for America’s future
Bringing to life the full story of biopharmaceutical innovation and investments
From sound to science: How IP powers innovation in music and hearing
Recognizing the value of disease prevention with Dr. Len Friedland from GSK
Congratulations to our 2024 Working for Cures Employee Champions
The importance of partnership: A conversation with Takeda
New research: American biopharmaceutical investment in R&D drives transformational innovation
The future of oncology R&D lies in policymakers’ hands
More than 60 researchers advocate on Capitol Hill
Alzheimer's & Brain Awareness Month: A conversation with Biogen
Alzheimer's & Brain Awareness Month: A conversation with Eisai
Alzheimer's & Brain Awareness Month: A conversation with Eli Lilly and Company
Powering the next generation of therapies: A conversation with Astellas US President Mark Reisenauer
Congratulations to our 2023 Working for Cures Employee Champions
Watch: Putting patients front and center for World AIDS Day
New Report: 1,600 cancer treatments and vaccines in clinical development
Watch: New video series spotlights advances in biopharmaceutical science
New report shows high-impact R&D happens after cancer medicines are first approved
More than 60 researchers ask Congress to support innovation
Biopharmaceutical science powered by PRIDE
Addressing Mental Health: A conversation with Barry Greene, CEO of Sage Therapeutics
World IP Day 2023: Celebrating women leaders in innovation
What we’ve learned from three years of fighting COVID-19
WTAS: Inflation Reduction Act already impacting R&D decisions
Sparking conversations — and careers — at the 2nd annual Pathways to Success Summit
Stories from the lab: Researchers discuss innovative treatments for cancers of the blood
Congratulations to our 2022 Working for Cures Employee Champions
Protecting against influenza: A conversation with David Ross, Vice President, Commercial Operations, North America, CSL Seqirus
An open letter to Congress: Stand with patients and future cures
PhRMA member companies’ R&D investments reach record high of $102.3 billion in 2021
Biopharmaceutical researchers to discuss the value of R&D with Congress
A conversation with Barry Greene, CEO of Sage Therapeutics
Stephanie Dyson of BMS on reducing health disparities
Biopharmaceutical industry drives economic growth in all 50 states
Guest post: Joining forces to combat the COVID-19 mental health crisis
Guest Series: PhRMA talks racial and health equity with Lauren Powell, VP US Health Equity and Community Wellness, Takeda
Industry leaders discuss the impact of the drug pricing debate
PhRMA member companies’ R&D investments reach record high of $91.1 billion in 2020
Watch: Building trust and enhancing clinical trial diversity
Building a better health care system: A conversation with Mark Reisenauer, President of Astellas US
Researchers to shine light on biopharmaceutical R&D with policymakers
Key takeaways: PhRMA comments to USPTO on how to make the innovation ecosystem more diverse and inclusive
Coming together to fight COVID-19: A conversation with Paul Perreault, CEO and Managing Director of CSL
Guest post: PhRMA talks racial and health equity with Stephanie Dyson, Head of Office at Biogen
Report highlights biopharmaceutical industry’s commitment to D&I
Guest Post: Bringing our best to the fight against COVID-19
An unprecedented year and the road ahead: A conversation with Giovanni Caforio, PhRMA Chairman and CEO of Bristol Myers Squibb
Coming together to fight COVID-19: A conversation with Peter Anastasiou, Executive Vice President of Lundbeck
New Report: The biopharmaceutical industry’s sustained commitment to inspiring and advancing tomorrow’s STEM workforce
Coming together to fight COVID-19: A conversation with Alexander Hardy, CEO of Genentech
Leading researchers to spotlight the critical role of biopharmaceutical R&D
Coming together to fight COVID-19: A conversation with Ramona Sequeira, President of Takeda Pharmaceuticals U.S.A
Coming together to fight COVID-19: A conversation with Albert Bourla, Chairman & CEO of Pfizer, Inc.
Guest Post: How proactivity and planning helped Novartis ensure a stable supply of medicines during COVID-19
PhRMA member companies invested $83 billion in research and development last year
Coming together to fight COVID-19: A conversation with Paul Hudson, CEO of Sanofi
Three ways the pharmaceutical industry can positively impact health equity
ICYMI: The latest as America’s biopharmaceutical companies work to beat COVID-19
New report explores setbacks that bring future cancer success stories
In combating COVID-19, science is how we get back to normal
Guest Post: Takeda seeks ‘new normal’ for cancer research during the COVID-19 pandemic
Guest Post: What will we learn from COVID-19?
Lilly, Merck and Pfizer empower team members to volunteer on COVID-19 frontlines
To the millions affected by COVID-19
Merck’s Dr. Julie Gerberding on the threat of antimicrobial resistance and COVID-19
The biopharmaceutical industry’s unique role in responding to COVID-19
ICYMI: America’s biopharmaceutical companies are working 'around the clock' to beat coronavirus
COVID-19 Response: Supporting the frontline
Guest post: Looking out for the invisibly vulnerable in the time of COVID-19
America’s biopharmaceutical companies are working around the clock to beat coronavirus
Guest post: Takeda’s efforts to address COVID-19
ICYMI: America’s biopharmaceutical companies are taking on COVID-19
ICYMI: Continued biopharmaceutical action on COVID-19
Working together to combat coronavirus
The journey to better health care requires a holistic view
Helping those affected by the 2017 hurricane season
Celebrating PRIDE in biopharmaceutical science
Guest Post: The importance of a modern FDA in drug discovery
Exploring the new era of medicine
Guest Post: Johnson and Johnson is celebrating outstanding scientists: Who will be next?
Watch: Biomarkers in drug development with Dr. Bernie Zeiher
Upcoming graduate student summit will showcase pathways to success within the biopharmaceutical industry
PhRMA Member Company
Upcoming graduate student summit will showcase pathways to success within the biopharmaceutical industry
Upcoming graduate student summit will showcase pathways to success within the biopharmaceutical industry